Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Adjuvanted Reduced Dose IPV in Infants
NCT03025750Phase 3Completed
- Sponsor
- Statens Serum Institut
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Picovax in poliomyelitis, sponsored by Statens Serum Institut. Started Jan 2017; status: completed.
02
Drugs
Picovax
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03025750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025750.